علاج السل اللميني للجهاز الهضمي في السل متعدد مقاومة الأدوية

References

• Multidrug-resistant TB (MDR-TB) continues to be a public health issue and a health security threat.
• Kanamycin (an injectable agent), moxifloxacin, prothionamide, clofazimine, isoniazid, pyrazinamide and ethambutol, given together in an initial phase of 4 months (with the option of extending to 6 months if the patient is still positive on a sputum smear at the end of month 4).
• Followed by an intensive phase of 5 months of treatment with four of the medicines (moxifloxacin, clofazimine, pyrazinamide, and ethambutol).
• Medicines are taken once per day, all days of the week.
• If the intensive phase is prolonged, the injectable agent is only given three times a week after the fourth month.